Biopharma Daily Stock Updates - 01/20/21

$XBI $154.13 (-0.09%) 📉


COVID:

$PFE (-0.65%) & $BNTX (-1.40%) - Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

https://biontechse.gcs-web.com/news-releases/news-release-details/pfizer-and-biontech-publish-results-study-showing-covid-19


$GRTS (+14.46%) - Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

http://ir.gritstoneoncology.com/news-releases/news-release-details/gritstone-and-genevant-sciences-announce-license-agreement-covid


PIPELINE:

$OCUL (-0.85%) - OCULAR THERAPEUTIX™ PRESENTS INTERIM TOPLINE DATA FROM THE PHASE 1 CLINICAL TRIAL OF OTX-TIC IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION AT THE 10TH ANNUAL GLAUCOMA 360 NEW HORIZONS FORUM

http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-presents-interim-topline-data-phase-1


$AZN (-0.63%) - EU approval

https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-eu-for-breast-cancer.html


$ARQT (-1.78%) - Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

https://investors.arcutis.com/news-releases/news-release-details/arcutis-advance-topical-roflumilast-foam-arq-154-phase-3


$ONCR (-5.00%) - ONCORUS ANNOUNCES PUBLICATION OF PRECLINICAL DATA DEMONSTRATING POTENT SYSTEMIC ANTITUMOR ACTIVITY OF ITS CLINICAL STAGE ONCOLYTIC HERPES SIMPLEX VIRAL IMMUNOTHERAPY PRODUCT CANDIDATE ONCR-177

https://investors.oncorus.com/news-releases/news-release-details/oncorus-announces-publication-preclinical-data-demonstrating


FMTX (-2.11%) - Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

https://ir.formatherapeutics.com/news-releases/news-release-details/forma-therapeutics-announces-first-patient-dosed-phase-1


FINANCIAL:

$TCRR (-2.85%) - Announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share.

https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-pricing-public-offering-1400-million


$ONCS (-5.11) - OncoSec Medical Announces Proposed Public Offering of Common Stock

https://ir.oncosec.com/press-releases/detail/2074/oncosec-medical-announces-proposed-public-offering-of


$ACRX (-17.02%) - AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock

https://ir.acelrx.com/news-releases/news-release-details/acelrx-announces-pricing-275-million-public-offering-common


$ACRS (-4.57%) - Pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.

http://investor.aclaristx.com/news-releases/news-release-details/aclaris-announces-pricing-public-offering-common-stock-2


$SYRS (-11.97%) - Priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share https://ir.syros.com/press-releases/detail/212/syros-announces-pricing-of-75-6-million-public-offering-of


$FULC (+18.93%) - Priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share

https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-pricing-public-offering-common


0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE